The National Cancer Institute’s Investigational New Drug program facilitates collaboration, not collusion, with industry for ...

Rutgers Health researchers have developed an oral antiviral drug candidate for COVID-19 that could overcome major limitations ...

The FDA granted a positive review for an acute myeloid leukemia drug trial, with initial dosing expected in 2025.

Durham-based Precision BioSciences Inc. has received investigational new drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for PBGENE-HBV, an in vivo gene editing program designed ...

Charles River Laboratories International, Inc. CRL and Valo Health, Inc. recently announced an advanced product candidate for the treatment of different forms of lupus and other autoimmune indications ...

A second phase 1 trial plans to evaluate CER-1236, a novel chimeric antigen receptor therapy, for solid tumors.

On March 5, 2025, the FDA cleared an investigational new drug application for CTD402, a CD7-targeted universal CAR T-cell therapy, for the treatment of pediatric and adult patients with ...

Corcept Therapeutics’ oral antiglucocorticoid plus chemotherapy slashed risk of ovarian cancer progression by 30% compared to ...

Inherited or genetic heart disorders, mostly known as Hypertrophic cardiomyopathy (HCM) in medical term, is a condition ...

Among patients with uncontrolled hypertension, the investigational drug lorundrostat brought a significant reduction in blood pressure at 12 weeks compared with placebo, according to a study presented ...